IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chan

Chandler Fulton, et al.

Title:

THIAMINASES AND THIAMINASE GENES

FOR USE IN APOPTOTIC THERAPIES

Appl. No.:

09/675,509

Filing Date:

9/29/2000

Examiner:

Ton, T.

Art Unit:

1632

Confirmation

1879

Number:

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attn: Appl. Processing Division, Customer Correction Branch

Sir:

Applicant acknowledges receipt from the PTO of the official Filing Receipt (dated April 13, 2001) in the above-referenced application.

There is an error with respect to the Domestic Priority data as claimed by applicant. The priority should read: THIS APPLN CLAIMS BENEFIT OF 60/156,952 09/29/1999.

Attached is a copy of the official Filing Receipt, marked up to show the requested correction. Also attached is a copy of the Declaration as filed on 1/22/2001, indicating the correct priority.

Issuance of a corrected Filing Receipt is respectfully requested.

The requested correction is not due to any error by Applicant and, accordingly, no fee is believed to be due. However, if any fees are required for processing of this submission, the Commissioner is authorized to charge any fees which may be required regarding this submission under 37 C.F.R §§ 1.16-1.17 or credit any overpayment to Deposit Account No. 19-0741.

Respectfully submitted,

Date 4/14/10

FOLEY & LARDNER LLP Customer Number: 30542

Telephone:

(858) 847-6767

Facsimile:

(858) 792-6773

Richard J. Warburg, Reg. No. 32,327

Stephen E. Reiter, Reg. No. 31,192

Attorneys for Applicant



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023

www.uspta.gov KET.NO DRAWINGS TOT CLAIMS IND CLAIMS

 APPLICATION NUMBER
 FILING DATE
 GRP ART UNIT
 FIL FEE REC'D
 ATTY.DOCKET.NO
 DRAWINGS
 TOT CLAIMS
 IND CLAIMS

 09/675,509
 09/29/2000
 2876
 540
 030598.0028.UTL1
 9
 11
 6

CONFIRMATION NO. 1879
CORRECTED FILING RECEIPT

[위문] 150 전 501 문) 문) 모두 대를 모르 보를 보는 'OC000000005968896*

Wesley B. Ames, Esq. FOLEY & LARDNER 23rd Floor 402 West Broadway San Diego, CA 92101-3542

Date Mailed: 04/13/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Chandler Fulton, Weston, MA; Elaine Y. Lai, Weston, MA;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 80/052,377 07/11/1997
AND CLAIMS BENEFIT OF 80/087,528 08/01/1998
AND CLAIMS BENEFIT OF 60/156,952 09/29/1999

Foreign Applications

If Required, Foreign Filing License Granted 11/07/2000

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

073442/0301 MDG MDG

Thiaminases and thiaminase genes for use in apoptotic therapies

Preliminary Class

235

Data entry by : GIZAW, ASTER

Team: OIPE

Date: 04/13/2001

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

DECLARATIONUtility Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention THIAMINASES AND THIAMINASE GENES FOR USE IN APOPTOTIC THERAPIES the specification of which

(Check One)	☐ is attached hereto OR ☐ was filed on September 29, 2000 as United States Application Serial No.
	was filed on <u>September 29, 2000</u> as United States Application Serial No. 09/675.509; PCT International Application No.
	and was amended on (if applicable).
I haraby state the	at I have reviewed and understand the contests of the above identified an effective

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed Yes No	

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date	
60/156,952	September 29, 1999	

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned	

Residence, post office address, citizenship and signature of inventor(s) set forth beginning on next page.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

	FULL NAME OF INVENTOR	FIRST Name Chandler	MIDDLE Initial	LAST Name Fulton	
201	RESIDENCE & CITIZENSHIP	City Weston	State or Foreign Country Massachusetts	Country of Citizenship United States of America	
	POST OFFICE ADDRESS	21 Hillcrest Road	City Weston	State or Country Massachusetts	Zip Code 02493
INVENTOR'S SIGNATURE Chandle Futh DATE 11 Jan. 200				. 2001	

INVENTOR'S SIGNATURE Elaine Y. Low DATE 11 Jan. 2001					
202	POST OFFICE ADDRESS	21 Hillcrest Road	City Weston	State or Country Massachusetts	Zip Code 02493
	RESIDENCE & CITIZENSHIP	City Weston	State or Foreign Country Massachusetts	Country of Citizenship United States of America	
	FULL NAME OF INVENTOR	FIRST Name Elaine	MIDDLE Initial Y.	LAST Name Lai	